Antares Pharma

We at Antares Pharma leverage our pharmaceutical and medical device expertise to develop innovative products that address needs in underserved therapeutic areas.

Our relentless pursuit of better therapies that positively affect patient lives inspires our employees to serve our customers and stakeholders every day.

News
& Media

Information contained in these press releases should be considered accurate only as of the date it was prepared. Information may change over time. Do not assume that the information remains accurate at a later date. Antares Pharma is not obligated to update the press releases and information contained in this section of the Company’s website.

 

Press Releases

22 November 2021
Antares Pharma to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

10 November 2021
Antares Pharma to Present at the Jefferies London Healthcare Conference

04 November 2021
Antares Pharma Reports Third Quarter 2021 Financial and Operating Results

28 October 2021
Antares Pharma Announces Appointment of Carmen Volkart to its Board of Directors

25 October 2021
Antares Pharma Announces Oral Presentation at the 22nd Annual Fall Scientific Meeting of SMSNA

21 October 2021
Antares Pharma to Report Third Quarter 2021 Financial and Operating Results

18 October 2021
Antares Pharma Enters Into Exclusive License Agreement with Lipocine for TLANDO® in U.S.

30 September 2021
Antares Pharma Initiates Phase I Study for ATRS-1902 for Adrenal Crisis Rescue

08 September 2021
Antares Pharma to Participate in the H.C. Wainright 23rd Annual Global Investment Conference

05 August 2021
Antares Pharma Reports Second Quarter 2021 Financial And Operating Results

28 July 2021
Antares Pharma to Report Second Quarter 2021 Financial and Operating Results

22 July 2021
Antares Pharma Announces FDA Acceptance of IND Application for ATRS 1902 For Adrenal Crisis Rescue

07 July 2021
Antares Pharma To Present At The Ladenburg Thalmann Annual Healthcare Conference

28 June 2021
Antares Pharma Announces Partner Idorsia Initiates The Phase 3 Study with Selatogrel For Acute Myocardial Infarction

22 June 2021
Antares Pharma Announces Submission of IND Application for ATRS 1902 For Adrenal Crisis Rescue

15 June 2021
Antares Pharma to Present at the Raymond James Human Health Innovations Conference

26 May 2021
Antares Pharma to Present at the Jefferies Virtual Healthcare Conference

06 May 2021
Antares Pharma Reports First Quarter 2021 Financial and Operating Results

06 May 2021
Antares Pharma Appoints Joseph Renda as Senior Vice President of Commercial

03 May 2021
Antares Pharma Announces Poster Presentation At The Pediatric Endocrine Society 2021 Virtual Annual Meeting

28 April 2021
Antares Pharma To Participate In The 7th Annual Truist Securities 2021 Life Sciences Summit

27 April 2021
Antares Pharma to Report First Quarter 2021 Financial and Operating Results

26 April 2021
Antares Pharma Appoints Dr. Peter Richardson As Executive Vice President, Research And Development And Chief Medical Officer

02 March 2021
Antares Pharma Reports Fourth Quarter and Full-Year 2020 Financial and Operating Results

24 February 2021
Antares Pharma to Present At Two Upcoming Investor Conferences

23 February 2021
Antares Pharma to Report Fourth Quarter And Full-Year 2020 Financial and Operating Results

17 February 2021
Antares Pharma to Participate in the SVB Leerink 10th Annual Virtual Global Healthcare Conference

11 January 2021
Antares Pharma Announces Full-Year 2021 Revenue Guidance of $175-200 Million